SYNERGISTIC ENHANCEMENT OF RESISTANCE TO CISPLATIN IN HUMAN BLADDER CANCER CELLS BY OVEREXPRESSION OF MUTANT-TYPE p53 AND Bcl-2
- 1 December 1999
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 162 (6) , 2176-2181
- https://doi.org/10.1016/s0022-5347(05)68155-4
Abstract
Purpose: The objective of this study was to characterize the effect of mutant-type p53 and Bcl-2 expression on the sensitivity to cisplatin in a human bladder cancer cell line both in vitro and in ...Keywords
This publication has 15 references indexed in Scilit:
- Long-Term results of neoadjuvant treatment with M-VAC (methotrexate, vinblastine, doxorubicin, and cisplatin) for locally invasive transitional cell carcinoma of the urotheliumInternational Journal of Clinical Oncology, 1999
- Overexpression of Bcl-2 in bladder cancer cells inhibits apoptosis induced by cisplatin and adenoviral-mediated p53 gene transferOncogene, 1998
- Absence of p53 Overexpression and Favorable Response to Cisplatin‐based Neoadjuvant Chemotherapy in Urothelial CarcinomasJapanese Journal of Cancer Research, 1998
- Expression of basic fibroblast growth factor is associated with resistance to cisplatin in a human bladder cancer cell lineCancer Letters, 1998
- Basic Fibroblast Growth Factor Regulates Matrix Metalloproteinases Production and In Vitro Invasiveness in Human Bladder Cancer Cell LinesJournal of Urology, 1997
- Expression of the mutated p53 tumor suppressor protein and its molecular and biochemical characterization in multidrug resistant MCF-7/Adr human breast cancer cellsOncogene, 1997
- Accumulation of Nuclear p53 and Tumor Progression in Bladder CancerNew England Journal of Medicine, 1994
- Bcl-2 and the regulation of programmed cell deathThe Journal of cell biology, 1994
- p53-dependent apoptosis modulates the cytotoxicity of anticancer agentsCell, 1993
- Mutations in the p53 gene occur in diverse human tumour typesNature, 1989